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Abstract
Background—Comparative effectiveness of interventional treatment strategies for the very
elderly with acute coronary syndrome remains poorly defined due to study exclusions.
Interventions include percutaneous coronary intervention (PCI), usually with stents, or coronary
artery bypass grafting (CABG). The elderly are frequently directed to PCI because of provider
perceptions that PCI is at therapeutic equipoise with CABG and that CABG incurs increased risk.
We evaluated long-term outcomes of CABG versus PCI in a cohort of very elderly Medicare
beneficiaries presenting with acute coronary syndrome.
Methods—Using Medicare claims data, we analyzed outcomes of multivessel PCI or CABG
treatment for a cohort of 10,141 beneficiaries age 85 and older diagnosed with acute coronary
syndrome in 2003 and 2004. The cohort was followed for survival and composite outcomes
(death, repeat revascularization, stroke, acute myocardial infarction) for three years. Logistic
regressions controlled for patient demographics and comorbidities with propensity score
adjustment for procedure selection.
Results—Percutaneous coronary intervention showed early benefits of lesser morbidity and
mortality, but CABG outcomes improved relative to PCI outcomes by three years (p < 0.01). At
36 months post-initial revascularization, 66.0% of CABG recipients survived (versus 62.7% of
PCI recipients, p < 0.05) and 46.1% of CABG recipients were free from composite outcome
(versus 38.7% of PCI recipients, p < 0.01).
Conclusions—In very elderly patients with ACS and multivessel CAD, CABG appears to offer
an advantage over PCI of survival and freedom from composite endpoint at three years.
Optimizing the benefit of CABG in very elderly patients requires absence of significant congestive
heart failure, lung disease, and peripheral vascular disease.
Elderly individuals are the fastest growing segment of the US population. Projections show
that those age 75 and older, currently 5% of the population, will triple in number by the
middle of this century, and those age 85 and older, currently 4.7 million, will double in
number to 9.6 million by 2030 [1,2]. With age comes an increasing incidence of
symptomatic coronary artery disease (CAD) requiring revascularization. Physicians will be
challenged to advise elderly patients to choose among medical management, percutaneous
coronary intervention (PCI), or coronary artery bypass surgery (CABG). Published
Address correspondence to Dr Sheridan, Division of Cardiothoracic Surgery, University of North Carolina, 3040 Burnett-Womack
Bldg, CB #7065, Chapel Hill, NC 27599-7065; sheridan@med.unc.edu.
Presented at the Fifty-sixth Annual Meeting of the Southern Thoracic Surgical Association, Marco Island, FL, Nov 4–7, 2009.
NIH Public Access
Author Manuscript
Ann Thorac Surg. Author manuscript; available in PMC 2010 July 22.
Published in final edited form as:













randomized trials comparing PCI with CABG demonstrate superior results for CABG in
terms of long-term (5 to 6 years) composite outcome of death, repeat revascularization,
repeat acute myocardial infarction (AMI), and stroke. Survival analysis from these same
trials have generally favored CABG, but these study populations excluded the very elderly
(age 85 and older) [3,4].
Outcomes among the very elderly in cardiac surgery are associated with increased morbidity
and mortality compared with outcomes for persons younger than 65 years [5]. A recent
systematic review with meta-analysis from investigators concluded that coronary
revascularization in octogenarians is reasonably tolerated but the preferred mechanism of
revascularization remains unresolved [6]. The Northern New England Cardiovascular
Disease Study Group evaluated their own experience in octogenarians with multivessel
disease undergoing PCI or CABG, concluding that CABG provided increased risk in the
short term but enhanced long-term survival (up to eight years) [7].
To compensate for low representation and to include current drug-eluting stent (DES)
therapy, we evaluated the comparative effectiveness of CABG versus PCI for very elderly
Medicare beneficiaries diagnosed with acute coronary syndrome (ACS) and multivessel
disease using a retrospective administrative database with a three-year follow-up period. The
study analyzes two outcomes over time: survival and freedom from composite endpoint of
death, myocardial infarction, stroke, and revascularization.
Material and Methods
This study was reviewed and approved by the University of North Carolina Biomedical
Institutional Review Board. To identify our sample (Fig 1), we selected data for Medicare
beneficiaries age 85 and older with an acute-care hospital Medicare Provider Analysis and
Review (MedPAR) discharge record from January 2003 through mid-October 2004 with an
ACS diagnosis and no diagnosis indicating prior (1 year) revascularization or valve disease.
The October 2004 requirement was necessary to comply with a CMS (Centers for Medicare
Medicaid Services) data request requirement of limiting our full sample to less than 1
million beneficiaries. Our sample therefore represents the full population of Medicare
beneficiaries meeting our sample inclusion and exclusion criteria from January 2003 through
mid-October 2004. This time period enabled our sample to include beneficiaries both before
and after the initiation of Medicare reimbursement for drug-eluting stents in April 2004.
This process identified the “index admission” and the MedPAR records prior to the index
admission were utilized to exclude patients with hospital stays identifying diagnoses or
procedures indicating revascularizations or other exclusion conditions (eg, valve disease,
heart transplant) prior to the index admission. The index admission record and subsequent
MedPAR records identified patients with PCI (diagnosis-related group [DRG] codes 516,
517, 555, 556 for bare-metal stents or codes 526, 527, 557, 558 for drug-eluting stents) or
CABG (DRG codes 106, 107, 109, 547, 548, 549, or 550) within 30 days at any hospital.
This iterative methodology created a data file with 28,571 patients; of those, 22,768 were
PCI patients with bare metal stents or DES (reimbursed by Medicare starting in April 2004)
and 5,803 underwent CABG. The PCI sample was limited to 4,338 patients with
intervention on more than one vessel (multivessel disease), resulting in a final analysis file
of 10,141 Medicare beneficiaries. Among the patients with PCI, 47.7% received bare metal
stents, 39.8% received DES, 8.3% received both types of stents, and 4.2% had PCI without a
stent.
Outcomes were identified through December 2007 by the following: (1) the Medicare
denominator file to observe date of death and (2) MedPAR hospital records to determine
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events of repeat hospitalization for revascularization, stroke, or subsequent AMI.
Beneficiary characteristics (age, gender, race, and state (Medicaid) Part B buy-in status)
came from the denominator file. Coding from the Agency for Healthcare Research and
Quality permitted construction of an Elixhauser comorbidity adjustment from diagnoses
during the index and revascularization admission as well as admissions for one year prior to
the index admission (see www.hcup-us.ahrq.gov/toolssoftware/comorbidity/ comorbidity.jsp
for the coding algorithm; we modified the coding to include indicators for primary disease
as well as comorbidities).
The analyses consisted of logistic regressions to determine the following: (1) the
characteristics associated with treatment selection (PCI or CABG); and (2) the effect of
CABG versus PCI on survival or time until the composite outcome of death, repeat
revascularization, stroke, or subsequent AMI. All regressions controlled for patient
characteristics and comorbidities. Results from the first logistic regression of procedure
choice (CABG vs PCI) were used to construct a propensity score included as an additional
covariate in the outcome regressions [8].
The outcomes analysis was limited to three years after the initial revascularization for which
we had complete follow-up information for the full sample. This approach simplified the
analysis by avoiding the need to make assumptions inherent in survival analysis techniques
(eg, we avoided the proportional hazard assumption implicit in Cox regression, as this
assumption was violated by the data). The three-year time period remains relevant for this
older population as this population is subject to mortality from competing risks. A series of
“stacked” logits using monthly outcomes were conducted using all observations free of the
specified outcomes at the beginning of each month. For example, for the analysis of
survival, the likelihood of surviving to the end of the first month after revascularization was
estimated using all observations; subsequently the observations that remained alive at the
end of the first month to estimate the (conditional) likelihood of surviving to the end of the
second month, repeating this process 35 times. Each “monthly” logistic regression provided
an estimate of surviving (ie, not dying, or not experiencing one of the four combined
outcomes of death, repeat revascularization, stroke, or acute myocardial infarction) for
persons receiving CABG versus PCI for multivessel disease. The logistic regression enabled
the generation of survival curves for the two treatment strategies. Confidence intervals were
generated from bootstrapping the survival estimates. To assess the relative impacts of patient
characteristics and comorbidities, two additional logistic regressions were completed: one
for the likelihood of surviving the first two months (“early” outcome) and a second
regression for surviving to 36 months conditional upon surviving the first two months
(“late” outcome). We present odds ratios for the patient characteristics and comorbidities to
assess the relative effects on the likelihood of “early” versus “late” survival/freedom from
death and the four combined outcomes.
Results
Sample characteristics at the time of the index admission (Table 1) demonstrate that based
on bivariate t tests, CABG beneficiaries appear to be slightly younger, more likely to be
male, have Part B deductible paid for by Medicaid. The CABG patients were less likely to
have a number of medical-comorbid conditions: ST-segment elevation myocardial infarction
(STEMI), congestive heart failure (CHF), hypothyroidism, depression, hypertension with
complications, or cancer. The first column of Table 2 provides the results for the logistic
regression for procedure choice (CABG vs PCI). Patients were more likely to be selected for
CABG if younger, male, and absent the following comorbidities: CHF, STEMI, depression,
hypertension with complications, or cancer. Patients with electrolyte irregularities were
more likely to receive CABG.
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The monthly logistic regression identified lower survival (p < 0.01) for CABG recipients the
first two months after primary revascularization, but CABG provided significantly better
survival (p < 0.05) and freedom from the composite outcome at 36 months (p < 0.01).
Monthly logistic regressions for adjusted outcomes (survival and freedom from composite
outcome) are shown in Figures 2 and 3, respectively. The adjusted survival curves cross in
favor of CABG at roughly 24 months with a 3.3% advantage at three years (p < 0.05).
Similarly, in the adjusted freedom from composite outcome cross in favor of CABG at
approximately five months with a 7.3 percentage- point advantage at three years (p < 0.01).
Both figures have 95% confidence intervals for the estimates of percent of patients surviving
or free from composite outcome at six-month intervals.
Because outcomes for CABG shifted from initially inferior to superior over time, the
additional columns of Table 2 provide coefficients from the logistic regressions for the
“early outcome” (death or composite outcome within the first two months after initial
revascularization) and “late outcome” (death or composite outcome at 36 months conditional
upon surviving or without composite outcome by two months post-revascularization). The
odds ratios for the effect of PCI on death or composite outcome reinforce the findings that
PCI recipients have lower likelihood of death or composite outcome early, but the likelihood
of death or manifesting a composite outcome is greater at three years. The odds ratio in
Table 2 also illustrates the effect of covariates.
In an attempt to understand factors associated with early (within two months of CABG)
versus late mortality (two to 36 months post-CABG conditional upon survival to two
months), a logistic regression was performed comparing documented descriptors (Table 3).
Early CABG death was associated with increasing age, STEMI, prior stroke, preexisting
CHF, and chronic obstructive pulmonary disease (COPD). Late CABG mortality was
associated with age, STEMI, prior stroke, preexisting CHF, COPD, diabetes and cancer.
Time-dependent factors such as progression of pre-procedure CHF and cancer appear to be
contributing to late CABG death.
As morbidity associated with procedures is critical to very elderly patients for decision
making, the breakdown of the composite endpoint (death, myocardial infarction, stroke, and
subsequent revascularization) is of interest. Figure 4 provides information on the unadjusted
rates of the four outcomes by three years after the initial revascularization. The outcomes are
not mutually exclusive, as patients may have experienced more than one of the outcomes
(eg, a patient may have suffered a stroke and then died) or may have experienced one of the
outcomes more than once in the three years after the initial revascularization. Although the
rate of stroke by 36 months was higher for persons revascularized by CABG, the rates of
death, repeat revascularization, and recurrent AMI were lower at 36 months for patients
initially receiving CABG versus PCI. Specifically, the rate of subsequent revascularizations
was more than four times higher in the PCI group (17.7% vs 4.0%). The incidence of AMI
was more than twice as frequent in the PCI group. All differences are significant (p < 0.01).
Comment
This retrospective analysis of Medicare claims data provides evidence of three-year
mortality and morbidity benefits of CABG in a large cohort of very elderly patients
presenting with ACS and multivessel CAD. Rates of survival and freedom from composite
morbidity are both initially higher for PCI recipients. Coronary artery bypass grafting
provides enhanced survival and freedom from composite morbidity at 36 months relative to
PCI. Comorbidities previously identified to negatively affect outcomes from CABG apply to
this population as well; COPD, CHF, peripheral vascular disease, and STEMI. The size of
the population studied, the availability of DES, and the broad demographic representation
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suggest that these findings are widely applicable in the current era. In appropriately selected
very elderly ACS patients with multivessel CAD, CABG remains a viable strategy despite
the availability of DES.
Given the improved survival and morbidity benefits over time for CABG versus PCI, an
important question is whether the initial mortality risk of CABG, its postsurgical functional
limitations, and its recovery period are worth the longer term survival advantage. Patients,
especially persons over age 85, may be willing to discount additional months of life for the
early benefits of PCI. Although this analysis prohibits an unambiguous recommendation for
CABG versus PCI for any particular patient, the results provide evidence that CABG may be
preferred and may provide improved outcomes for selected patients. Albeit speculative, the
advantage of surgery may arise from a more complete revascularization strategy and (or) the
durability advantages of left internal thoracic artery grafts. The Synergy between PCI with
the Taxus and Cardiac Surgery (SYNTAX) trial published a higher risk of stroke with
CABG compared with left main PCI [9], and our results are consistent with this observation.
The incidence of stroke was surprisingly high in both treatment groups with an increased
incidence in CABG patients. It is possible that this analysis of very elderly patients has
identified a particularly high-risk patient population that is highly vulnerable to
cerebrovascular complications of coronary revascularization.
Interest in the elderly and the very elderly is growing, as they account for an increasing
share of the US population. Unfortunately, prospective randomized controlled trials have
excluded older patients, which limit insight into this vulnerable group. More recent trials
such as the Trial of Invasive versus Medical therapy in Elderly (TIME) have enrolled a
greater number of older patients [10] but the over-80-year-old group remains
underrepresented. Alexander and colleagues [11] successfully used the National
Cardiovascular Network to study cardiac surgery outcomes in octogenarians. This
thoughtful analysis observed that appropriately selected octogenarians could successfully
undergo cardiac surgery with acceptable risk. In a single-center review, Akins and
colleagues [5] identified 600 consecutive octogenarians undergoing cardiac operations. They
not only demonstrated reasonable five-year survival but also observed that at five years,
survival normalized with the general US octogenarian population. Extending beyond the
single-center experience to a regional analysis, the Northern New England Cardiovascular
Disease Study Group [7] evaluated 1,693 octogenarians undergoing PCI or CABG for
multivessel disease. They identified a short-term advantage with PCI at six months with a
long-term benefit of CABG over the subsequent eight-year follow-up. This retrospective
regional study was followed by a large meta-analysis published by the Mayo Clinic
essentially confirming the above and advocating for prospective randomized controlled trials
to provide enhanced evidence [6]. Finally, the recently published SYNTAX trial is a
prospective randomized controlled trial comparing CABG with multivessel PCI using
exclusively DES [9]. The SYNTAX population had a mean age of 65 years and excluded
AMI patients, and therefore differed substantially from the current study. Moreover, the
cohort analyzed presently is substantially larger, with two additional years of follow-up. No
randomized trials of myocardial revascularization are currently planned in the 85-and-older
population, which increases the importance of observational studies to provide data from
real-world clinical practice to aid decision making.
Despite these strengths, this study has several limitations. It is a retrospective administrative
analysis without clinical records such as ejection fraction. As medical record data were
unavailable, the comorbidity data reflect only those codes included on the MedPAR claims
and may underestimate the true prevalence of comorbid disease in the population due to
missing data or important unobserved health status measures. Administrative data may also
over-represent new conditions such as stroke. While propensity score adjustment of the
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treatment groups for comorbidities and other clinical and demographic characteristics
improves the precision of these results, unmeasured differences may persist and result in
significant confounding. Additional factors, including onset of comorbidities over time,
socioeconomic status, support systems, premorbid functional status, and hospital and health
care providers, may have influenced treatment selection beyond the controlling influence of
the propensity adjustment methodology. Although unavailable, this study would also benefit
from outcomes data specifying functionality (activities of daily living and self-report
questionnaire) as well as a cost analysis.
In very elderly patients with ACS and multivessel CAD, CABG appears to offer an
advantage over PCI of survival and freedom from composite endpoint at three years. To
optimize the benefit of CABG in very elderly patients requires the absence of significant
CHF, lung, and peripheral vascular disease. Despite improved safety of PCI and the
development of drug-eluting stents, the advantage of CABG (albeit modest) over PCI
appears to persist even after age 85. Improved patient selection, enhanced surgical
techniques, and postprocedural care sensitive to the unique physiology in this vulnerable
population will ensure that CABG remains an important therapeutic option for the treatment
of multivessel CAD in this population.
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Abbreviations and Acronyms
ACS acute coronary syndrome
AMI acute myocardial infarction
CABG coronary artery bypass graft
CAD coronary artery disease
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
DES drug-eluting stents
MedPAR Medicare Provider Analysis and Review
OR odds ratios
PCI percutaneous coronary intervention
RCT randomized controlled trials
STEMI ST-segment elevation myocardial infarct
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Diagram of cohort identification and exclusions. (ACS = acute coronary syndrome; CABG
= coronary artery bypass graft; MedPAR = Medicare Provider Analysis and Review; PCI =
percutaneous coronary intervention.)
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Adjusted survival with confidence interval for persons age 85 and older. (CABG = coronary
artery bypass graft; PCI = percutaneous coronary intervention; p < 0.05.)
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Adjusted freedom from composite outcome (composite of death, repeat revascularization,
stroke and acute myocardial infarction) for persons age 85 and older. (CABG = coronary
artery bypass graft; PCI = percutaneous coronary intervention; p < 0.01.)
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Unadjusted 3-year composite outcomes (not mutually exclusive) for patients age 85 and
older. (CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention; p <
0.01 for all groups.)
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Table 1
Cohort Descriptive Statistics
Descriptor Full Sample CABG PCI p Value
Number of observations 10,141 5,803 4,338
Beneficiary characteristics
 Age 87.2 86.8 87.7 0.000
 Non-white 5.2% 5.1% 5.3% 0.722
 Male 49.4% 54.9% 41.9% 0.000
 State Medicaid buy-in 8.2% 6.7% 10.2% 0.000
Comorbidities prior to index admission
 Prior stroke 5.7% 5.7% 5.9% 0.629
 CHF 7.6% 6.3% 9.4% 0.000
 Valvular disease 4.1% 3.9% 4.4% 0.283
Conditions/comorbidities prior to/including index admission
 STEMI 20.6% 17.8% 24.3% 0.000
 Pulmonary circulatory disease 3.6% 3.6% 3.6% 0.976
 Peripheral vascular disease 14.5% 15.0% 13.8% 0.097
 COPD 18.4% 18.9% 17.8% 0.164
 Hypothyroidism 13.4% 12.3% 15.0% 0.000
 Electrolyte irregularity 22.1% 25.0% 18.3% 0.000
 Depression 3.5% 3.1% 4.0% 0.010
 Hypertension with complications 72.9% 71.2% 75.2% 0.000
 Diabetes mellitus 21.6% 21.3% 22.0% 0.410
 Cancer 3.7% 3.3% 4.3% 0.013
 Anemia 16.8% 16.4% 17.3% 0.236
CABG = coronary artery bypass graft; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; PCI = percutaneous
coronary intervention; STEMI = ST-segment elevation myocardial infarction.
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Table 3
Factors Associated With Mortality Less Than Two Months After CABG Surgery
Factor Odds Ratio (95% CI) p Value
Age 1.06 (1.02–1.20) 0.004
Male 0.74 (0.63–0.87) 0.000
STEMI 1.81 (1.51–2.16) 0.000
Prior stroke 1.45 (1.07–1.97) 0.017
Preexisting CHF 1.88 (1.40–2.51) 0.000
COPD 1.32 (1.10–1.59) 0.003
Diabetes 0.79 (0.65–0.97) 0.023
CABG = coronary artery bypass graft; CHF = congestive heart failure; CI = confidence interval; COPD = chronic obstructive pulmonary disease;
STEMI = ST-segment elevation myocardial infarction.
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